177 related articles for article (PubMed ID: 22019059)
1. A meta-analysis of randomized head-to-head trials of atorvastatin versus rosuvastatin for reductions in C-reactive protein.
Takagi H; Umemoto T
Int J Cardiol; 2012 Jan; 154(1):78-81. PubMed ID: 22019059
[No Abstract] [Full Text] [Related]
2. Atorvastatin, not rosuvastatin, improves cardiac function in heart failure: a meta-analysis of randomized trials.
Takagi H; Umemoto T
Int J Cardiol; 2012 Mar; 155(2):296-9. PubMed ID: 22200185
[No Abstract] [Full Text] [Related]
3. A meta-analysis of randomized head-to-head trials for effects of rosuvastatin versus atorvastatin on apolipoprotein profiles.
Takagi H; Umemoto T;
Am J Cardiol; 2014 Jan; 113(2):292-301. PubMed ID: 24230979
[TBL] [Abstract][Full Text] [Related]
4. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials.
Wlodarczyk J; Sullivan D; Smith M
Am J Cardiol; 2008 Dec; 102(12):1654-62. PubMed ID: 19064019
[TBL] [Abstract][Full Text] [Related]
5. Is rosuvastatin really a more efficient therapeutic option than atorvastatin?
Soto J; Fernandez de Bobadilla J
Value Health; 2006; 9(4):276-7; author reply 277-9. PubMed ID: 16903999
[No Abstract] [Full Text] [Related]
6. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study).
Betteridge DJ; Gibson JM; Sager PT
Am J Cardiol; 2007 Oct; 100(8):1245-8. PubMed ID: 17920365
[TBL] [Abstract][Full Text] [Related]
7. [Comment from the cardiologic viewpoint].
Lüscher TF
Praxis (Bern 1994); 2009 Feb; 98(3):129-30. PubMed ID: 19180438
[No Abstract] [Full Text] [Related]
8. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study.
Stalenhoef AF; Ballantyne CM; Sarti C; Murin J; Tonstad S; Rose H; Wilpshaar W
Eur Heart J; 2005 Dec; 26(24):2664-72. PubMed ID: 16143705
[TBL] [Abstract][Full Text] [Related]
9. From CARDS to AURORA: one disease, two responses.
Escobar C; Barrios V; Echarri R
Hellenic J Cardiol; 2010; 51(3):281. PubMed ID: 20515865
[No Abstract] [Full Text] [Related]
10. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
11. [The JUPITER study].
Gaspardone A; Maseri A
G Ital Cardiol (Rome); 2009 May; 10(5):267-70. PubMed ID: 19537439
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
Schwartz GG; Bolognese MA; Tremblay BP; Caplan R; Hutchinson H; Raza A; Cressman M
Am Heart J; 2004 Jul; 148(1):e4. PubMed ID: 15215813
[TBL] [Abstract][Full Text] [Related]
13. [Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): -- the PATROL trial].
Saku K; Zhang B; Noda K
Nihon Naika Gakkai Zasshi; 2011 Dec; 100(12):3679-86. PubMed ID: 22338904
[No Abstract] [Full Text] [Related]
14. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
[TBL] [Abstract][Full Text] [Related]
15. Dramatic reductions in plaque volumes on maximum statin therapy.
Cardiovasc J Afr; 2011; 22(6):344-5. PubMed ID: 22159326
[No Abstract] [Full Text] [Related]
16. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes.
Betteridge DJ; Gibson JM
Diabet Med; 2007 May; 24(5):541-9. PubMed ID: 17367312
[TBL] [Abstract][Full Text] [Related]
17. Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis.
Savarese G; Musella F; Volpe M; Paneni F; Perrone-Filardi P
Int J Cardiol; 2013 Sep; 167(6):2482-9. PubMed ID: 22633671
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: results of the CENTAURUS study.
Lablanche JM; Leone A; Merkely B; Morais J; Alonso J; Santini M; Eha J; Demil N; Licour M; Tardif JC;
Arch Cardiovasc Dis; 2010 Mar; 103(3):160-9. PubMed ID: 20417447
[TBL] [Abstract][Full Text] [Related]
19. Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design.
Lablanche JM; Danchin N; Farnier M; Tedgui A; Vicaut E; Alonso J; Crean P; Leone A; Morais J; Santini M; Licour M; Farah M; Tardif JC
Arch Cardiovasc Dis; 2008 Jun; 101(6):399-406. PubMed ID: 18809153
[TBL] [Abstract][Full Text] [Related]
20. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol.
Bergheanu SC; Van Tol A; Dallinga-Thie GM; Liem A; Dunselman PH; Van der Bom JG; Jukema JW
Curr Med Res Opin; 2007 Sep; 23(9):2235-40. PubMed ID: 17692153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
